Xylazine Wounds: How Skin Ulcers Are Treated During Detox

Xylazine wounds are areas of skin ulceration and tissue death linked to xylazine, a veterinary sedative found in the illicit opioid supply. They appear near and far from injection sites because the drug narrows small blood vessels and starves the skin of oxygen. Healing depends on treating the underlying substance use, not dressings alone.

The wound is often the reason someone finally picks up the phone. Not the sedation, not the missed days, not the money — the wound. A patch of skin on the forearm or calf that started as a small dark area and, over weeks, opened, spread, and stopped closing. By the time it is described to us over the phone, it usually looks worse than any injury the person has had before, and it is frequently in a place they never injected.

That last detail is what unsettles people most. You expect damage where the needle went. You do not expect a wound to open on the opposite limb, or on skin you barely touched. It feels like the body has turned on itself for no reason, and it is easy to read that as a sign the situation is hopeless. It is not. It is a recognisable clinical pattern, and it responds to the right sequence of care.

This post is about that sequence. It is written as much for the person living with the wound as for the family member or partner reading this on someone else’s behalf — quietly, late at night, trying to understand what they are looking at before they raise it. If that is you, you are exactly who we have in mind here too. If you want the background — what xylazine is, how it reached the street supply, why it is mixed with fentanyl — we cover that in a companion piece on what xylazine is and how it entered the drug supply. Here we stay on one question: why these wounds behave the way they do, and what wound care during a medically supervised admission actually involves.

Why do xylazine wounds appear even where the needle never went?

Because the injury is driven by the drug’s effect on blood vessels, not only by the puncture. Xylazine is an alpha-2 adrenergic agonist, and in the periphery it narrows small arterioles in the skin, cutting local blood flow and leaving tissue short of oxygen.

When perfusion drops far enough, skin cells begin to die and the surface breaks down into an ulcer. Because the drug circulates rather than staying at the puncture, the reduced perfusion is not confined to injection sites. The National Institute on Drug Abuse notes that repeated xylazine use is associated with skin ulcers and abscesses, and that clinicians have seen these wounds develop away from injection sites and even in people who smoke or snort rather than inject (NIDA). Researchers describe the pathogenesis as multifactorial — vasoconstriction and poor perfusion alongside cytotoxic effects, repeated injection trauma, and prolonged pressure during sedation (PMC).

What makes a xylazine wound different from an ordinary abscess?

An ordinary injection abscess is a contained pocket of infection that drains and closes once treated. A xylazine wound is a slow-healing ulcer over tissue that is being actively starved of blood, so it resists the usual course.

The practical difference is time and behaviour. These wounds tend to be deeper, wider, and far slower to granulate than a standard skin infection. In one published case series, a single wound took 190 days to reach full granulation coverage even with sustained treatment (PMC). The severity has pushed clinicians to build dedicated tools — the HEAL-X system was created specifically to standardise how xylazine-associated wounds are assessed and staged, because existing wound scales did not capture what they were seeing (PMC).

Why isn’t wound care alone enough to heal a xylazine wound?

Because ongoing use keeps re-supplying the drug that is causing the vasoconstriction. You can dress a wound perfectly and it will still struggle to close while fresh xylazine continues to narrow the vessels feeding that skin.

This is the point families most often miss. Clean dressings, antibiotics, and even skilled surgical debridement address what has already happened to the tissue. None of them change the input. As long as the substance is still being used, the skin is repeatedly returned to the low-perfusion state that opened the wound in the first place, and healing stalls. It is common for a person to have cycled through emergency departments and dressing changes for months, seeing the wound improve briefly and then reopen, and to conclude that nothing works. What was missing was not better wound care but a setting where the drug driving the injury could be removed at the same time. This is why we treat a xylazine wound as a sign that supervised withdrawal is needed, not as a standalone dermatological problem.

What does wound care look like during a medically supervised admission?

It runs in parallel with detox: the wound is cleaned, assessed, and dressed on a schedule while withdrawal is managed clinically and safely. Neither part waits for the other.

On the wound side, daily care typically means gentle cleansing, staging of the tissue, topical treatment where indicated, and regular dressing changes chosen for the wound’s depth and drainage — the practical elements described across the clinical literature (PMC). Deeper wounds may need review by a wound-care specialist or surgical input. On the withdrawal side, it is important to understand that xylazine is not an opioid and naloxone does not reverse it, and it has no approved human use or established antidote (NIDA). Because it is almost always mixed with fentanyl, withdrawal is layered, and the opioid component is often managed with maintenance medication — the context we cover in our note on Suboxone and opioid maintenance. All of this is coordinated by our Dual Treatment programme, so the substance use and any co-occurring behavioural health needs are addressed together rather than in sequence.

How does stopping use change the wound itself?

Once the drug is no longer narrowing the vessels, perfusion to the affected skin can recover, and the wound is finally able to move through the healing it could not reach before. The dressings stop working against a moving target.

This does not happen overnight, and we are honest with patients and families about that. Skin that has been ischaemic for months does not close in days, and some wounds need weeks of consistent care before granulation is well established. Larger or deeper wounds may still need specialist review, and a minority go on to require surgical input. What changes is the direction of travel: with use stopped and care in place, the wound is trending toward closure instead of quietly worsening. For many patients that shift is the first concrete evidence that the decision to come in was the right one, and it does a great deal for morale during an otherwise hard early stretch.

“Families arrive focused entirely on the wound, and understandably so — it is frightening to look at. But the wound is the visible edge of a circulation problem the drug keeps re-creating. Our job is to hold both truths at once: care for the skin every single day, and remove the thing that is starving it. When we do both, wounds that looked static for months finally start to change.” — Dr. Natalie Lindemann, Clinical Director (Global), Holina Global

What we watch for in the first weeks of admission

We monitor for signs of deeper infection, changes in wound size and colour, and the wider withdrawal picture, because a xylazine wound rarely arrives alone. The scale of the problem is not small: across 21 US jurisdictions, the share of illicitly manufactured fentanyl-involved deaths with xylazine detected rose 276% — from 2.9% to 10.9% — between January 2019 and June 2022 (CDC MMWR), and testing gaps mean the true figure is likely higher.

Alongside the clinical monitoring, admission is when we bring families into the picture through family addiction support, because a visible, slow-healing wound places real strain on the people around the patient. If you are weighing whether now is the time, you can start the intake process or simply speak with our team first.

Wound Care and Medical Support at Holina Rehab

Everything above is easier to deliver in a residential setting than through intermittent outpatient visits, which is how we have built the programme here. Holina Rehab sits on a beachfront campus on Koh Phangan, Thailand, and admission means a person is living on-site for the duration of their stay rather than returning to the environment where use continued. That matters for a xylazine wound specifically: daily cleansing, staging, dressing changes, and monitoring for deeper infection can happen on a consistent schedule, carried out by our on-site medical and nursing team, without the gaps that let a wound reopen between appointments.

The medical side runs alongside, not ahead of, the clinical work. Withdrawal is supervised on-site through the acute detox period, and the wider treatment plan is delivered through our Dual Treatment programme, which addresses substance use and any co-occurring behavioural health needs together. The programme is structured in 30, 60, and 90-day tiers, so the length of stay can be matched to how entrenched the use is and, in these cases, to how much healing time a slow-granulating wound realistically needs. Clinical oversight sits with our Clinical Director, Dr. Natalie Lindemann, and the day-to-day medical and nursing care is coordinated as one plan rather than handed between disconnected services.

Frequently asked questions

Are xylazine wounds a sign of addiction to xylazine specifically?

Not usually on their own. Xylazine is most often found mixed into illicit fentanyl, so people are frequently exposed without seeking it out. The wound reflects xylazine exposure, but the underlying dependence is typically to the opioid it is mixed with.

Can a xylazine wound be treated without stopping drug use?

Wounds can be cleaned and dressed at any point, and harm-reduction wound care matters. But because ongoing use keeps constricting the blood vessels that feed the skin, wounds tend to stall until use is addressed under medical supervision.

Does naloxone reverse xylazine?

No. Xylazine is not an opioid, and naloxone does not reverse its sedative effects. Because it is usually combined with fentanyl, naloxone is still given in an overdose to reverse the opioid component (NIDA).

Why do the wounds appear away from injection sites?

Because the injury is driven largely by reduced blood flow to the skin rather than by the puncture itself. This is also why wounds have been reported in people who smoke or snort rather than inject.

How long does a xylazine wound take to heal?

It varies widely with depth and how long the tissue has been affected. Published cases describe wounds taking many weeks to months to fully granulate, even with consistent treatment.

Do these wounds always need surgery?

No. Many are managed with cleansing, staging, topical care, and regular dressing changes. Deeper wounds may need specialist wound-care review or, in some cases, surgical debridement or grafting.

Is the wound dangerous by itself?

It can become dangerous if it develops a deeper infection, which is one reason supervised care matters. During admission we monitor for signs of spreading infection and escalate care when needed.

Will detox make the wound worse before it gets better?

Detox does not worsen the wound. Removing the substance stops the ongoing vasoconstriction, which is what allows healing to progress. Wound care continues throughout the withdrawal period.

What is Dual Treatment and why does it matter here?

Dual Treatment means addressing substance use and any co-occurring behavioural health needs together rather than one after the other. With xylazine wounds it lets us coordinate withdrawal, wound care, and psychological support as one plan.

Can we call before deciding on admission?

Yes. You can speak with our team to talk through the wound, the withdrawal picture, and what admission would involve before committing to anything.

Clinically reviewed by Dr. Natalie Lindemann — Clinical Director, Holina Global · Last reviewed 20 July 2026.